II期临床试验-话题@MedSci

#II期临床试验#

174篇内容 | 3280人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1931484, encodeId=255e1931484be, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=**名患者参加勃林格殷格翰的钠通道抑制剂治疗囊性纤维化的II期临床试验, objectType=article, longId=181606, objectId=fdfc181606fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdfc181606fb, replyNumber=0, likeNumber=72, createdTime=2020-02-10, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdfc181606fb, moduleTitle=**名患者参加勃林格殷格翰的钠通道抑制剂治疗囊性纤维化的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdfc181606fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931485, encodeId=157a19314856f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Pamrevlumab治疗局部晚期胰腺癌的III期临床试验正式开始, objectType=article, longId=181869, objectId=b55d181869fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b55d181869fc, replyNumber=0, likeNumber=56, createdTime=2019-11-04, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b55d181869fc, moduleTitle=Pamrevlumab治疗局部晚期胰腺癌的III期临床试验正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b55d181869fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931475, encodeId=31d619314e52e, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=斑秃靶向治疗：口服ATI-501治疗斑秃的II期临床试验达到其主要终点, objectType=article, longId=176549, objectId=9a1f1e654908, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a1f1e654908, replyNumber=0, likeNumber=101, createdTime=2020-05-12, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a1f1e654908, moduleTitle=斑秃靶向治疗：口服ATI-501治疗斑秃的II期临床试验达到其主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a1f1e654908)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931507, encodeId=699e193150e77, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Merimepodib治疗COVID-19的II期临床试验：即将开始, objectType=article, longId=193035, objectId=ed7619303569, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed7619303569, replyNumber=0, likeNumber=76, createdTime=2020-12-14, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed7619303569, moduleTitle=Merimepodib治疗COVID-19的II期临床试验：即将开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed7619303569)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931488, encodeId=9132193148840, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=儿童造血干细胞移植相关的血栓性微血管病：Nomacopan关键性III期临床试验, objectType=article, longId=185186, objectId=397c185186ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=397c185186ea, replyNumber=0, likeNumber=0, createdTime=2020-04-24, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=397c185186ea, moduleTitle=儿童造血干细胞移植相关的血栓性微血管病：Nomacopan关键性III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=397c185186ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931491, encodeId=61e419314915c, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始, objectType=article, longId=185522, objectId=448618552283, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=448618552283, replyNumber=0, likeNumber=52, createdTime=2020-06-12, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=448618552283, moduleTitle=RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=448618552283)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931493, encodeId=f688193149334, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=用细菌抗击细菌！微生物群药物RBX2660已完成III期临床试验的注册, objectType=article, longId=187585, objectId=d55418e58511, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d55418e58511, replyNumber=0, likeNumber=41, createdTime=2020-11-22, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d55418e58511, moduleTitle=用细菌抗击细菌！微生物群药物RBX2660已完成III期临床试验的注册, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d55418e58511)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931478, encodeId=3c3c19314e8b6, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功, objectType=article, longId=177714, objectId=d4e41e7714e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4e41e7714e1, replyNumber=0, likeNumber=74, createdTime=2019-10-18, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4e41e7714e1, moduleTitle=阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4e41e7714e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931506, encodeId=b41f19315064f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=II期临床试验测试Vafidemstat治疗重症COVID-19患者的疗效, objectType=article, longId=193033, objectId=b12819303320, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b12819303320, replyNumber=0, likeNumber=67, createdTime=2020-10-28, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b12819303320, moduleTitle=II期临床试验测试Vafidemstat治疗重症COVID-19患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b12819303320)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931480, encodeId=8a5a1931480e3, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=BT-11治疗溃疡性结肠炎的全球II期临床试验已正式开始, objectType=article, longId=178054, objectId=7b581e8054f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b581e8054f4, replyNumber=0, likeNumber=92, createdTime=2020-04-20, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b581e8054f4, moduleTitle=BT-11治疗溃疡性结肠炎的全球II期临床试验已正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b581e8054f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931503, encodeId=39db19315031e, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准, objectType=article, longId=191868, objectId=b01e191868d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b01e191868d2, replyNumber=0, likeNumber=49, createdTime=2020-08-26, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b01e191868d2, moduleTitle=OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b01e191868d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931496, encodeId=45e4193149650, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=脑肿瘤一线治疗：VAL-083的II期临床试验即将开始, objectType=article, longId=188493, objectId=779818849367, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=779818849367, replyNumber=0, likeNumber=122, createdTime=2020-11-21, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=779818849367, moduleTitle=脑肿瘤一线治疗：VAL-083的II期临床试验即将开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=779818849367)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931476, encodeId=7c2c19314e673, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功, objectType=article, longId=177339, objectId=a5a91e73396a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5a91e73396a, replyNumber=0, likeNumber=64, createdTime=2020-02-14, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5a91e73396a, moduleTitle=阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5a91e73396a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931470, encodeId=481419314e059, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=FDA批准MRT5201进行单次剂量递增的I/II期临床试验，用于鸟氨酸氨甲酰基转移酶缺乏症, objectType=article, longId=174342, objectId=3d2b1e4342ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d2b1e4342ca, replyNumber=0, likeNumber=72, createdTime=2019-11-28, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d2b1e4342ca, moduleTitle=FDA批准MRT5201进行单次剂量递增的I/II期临床试验，用于鸟氨酸氨甲酰基转移酶缺乏症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d2b1e4342ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931462, encodeId=5f8619314625c, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点, objectType=article, longId=165652, objectId=69a116565258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69a116565258, replyNumber=0, likeNumber=54, createdTime=2019-09-25, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69a116565258, moduleTitle=慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69a116565258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931465, encodeId=963c193146505, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=AAN：II期临床试验证实口服Bruton酪氨酸激酶（BTK）抑制剂治疗多发性硬化症的有效性, objectType=article, longId=165920, objectId=671e16592080, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=671e16592080, replyNumber=0, likeNumber=69, createdTime=2019-07-12, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=671e16592080, moduleTitle=AAN：II期临床试验证实口服Bruton酪氨酸激酶（BTK）抑制剂治疗多发性硬化症的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=671e16592080)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931479, encodeId=997d19314e97e, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Knopp Biosciences宣布开始II期临床试验评估右旋普拉克索在嗜酸性粒细胞性哮喘中的应用, objectType=article, longId=177982, objectId=e7881e798242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7881e798242, replyNumber=0, likeNumber=60, createdTime=2020-01-02, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7881e798242, moduleTitle=Knopp Biosciences宣布开始II期临床试验评估右旋普拉克索在嗜酸性粒细胞性哮喘中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7881e798242)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931494, encodeId=cd1c193149439, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=通用型流感疫苗M-001的II期临床试验取得积极结果, objectType=article, longId=187590, objectId=c62918e5909e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c62918e5909e, replyNumber=0, likeNumber=59, createdTime=2021-01-18, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c62918e5909e, moduleTitle=通用型流感疫苗M-001的II期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c62918e5909e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931460, encodeId=83a519314600a, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险, objectType=article, longId=164340, objectId=bc7c1643405d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc7c1643405d, replyNumber=0, likeNumber=71, createdTime=2019-10-31, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc7c1643405d, moduleTitle=III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc7c1643405d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931458, encodeId=638d193145833, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验, objectType=article, longId=163509, objectId=ad4a1635092f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad4a1635092f, replyNumber=0, likeNumber=107, createdTime=2020-01-12, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad4a1635092f, moduleTitle=和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad4a1635092f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床试验

2020-05-29

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

**名患者参加勃林格殷格翰的钠通道抑制剂治疗囊性纤维化的II期临床试验

2020-02-10

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Pamrevlumab治疗局部晚期胰腺癌的III期临床试验正式开始

2019-11-04

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

斑秃靶向治疗：口服ATI-501治疗斑秃的II期临床试验达到其主要终点

2020-05-12

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Merimepodib治疗COVID-19的II期临床试验：即将开始

2020-12-14

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

儿童造血干细胞移植相关的血栓性微血管病：Nomacopan关键性III期临床试验

2020-04-24

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始

2020-06-12

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

用细菌抗击细菌！微生物群药物RBX2660已完成III期临床试验的注册

2020-11-22

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

阿斯利康和MSD的PARP抑制剂Lynparza治疗晚期卵巢癌的III期临床试验成功

2019-10-18

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

II期临床试验测试Vafidemstat治疗重症COVID-19患者的疗效

2020-10-28

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

BT-11治疗溃疡性结肠炎的全球II期临床试验已正式开始

2020-04-20

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准

2020-08-26

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

脑肿瘤一线治疗：VAL-083的II期临床试验即将开始

2020-11-21

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

阿斯利康和MSD宣布其PARP抑制剂Lynparza治疗前列腺癌的III期临床试验成功

2020-02-14

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

FDA批准MRT5201进行单次剂量递增的I/II期临床试验，用于鸟氨酸氨甲酰基转移酶缺乏症

2019-11-28

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点

2019-09-25

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

AAN：II期临床试验证实口服Bruton酪氨酸激酶（BTK）抑制剂治疗多发性硬化症的有效性

2019-07-12

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Knopp Biosciences宣布开始II期临床试验评估右旋普拉克索在嗜酸性粒细胞性哮喘中的应用

2020-01-02

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

通用型流感疫苗M-001的II期临床试验取得积极结果

2021-01-18

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险

2019-10-31

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验

2020-01-12

科室
- - 订阅+
  - 更多科室
工具
服务